4 Analysts Have This To Say About Revvity

During the last three months, 4 analysts shared their evaluations of Revvity RVTY, revealing diverse outlooks from bullish to bearish.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 1 2 1 0 0
Last 30D 1 0 0 0 0
1M Ago 0 0 0 0 0
2M Ago 0 0 0 0 0
3M Ago 0 2 1 0 0

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $123.25, along with a high estimate of $130.00 and a low estimate of $110.00. Witnessing a positive shift, the current average has risen by 13.59% from the previous average price target of $108.50.

price target chart

Decoding Analyst Ratings: A Detailed Look

The perception of Revvity by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Dan Brennan TD Cowen Raises Buy $130.00 $123.00
Daniel Arias Stifel Raises Hold $110.00 $95.00
Paul Knight Keybanc Raises Overweight $126.00 $110.00
Andrew Cooper Raymond James Raises Outperform $127.00 $106.00

Key Insights:

  • Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Revvity. This information offers a snapshot of how analysts perceive the current state of the company.
  • Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Revvity compared to the broader market.
  • Price Targets: Understanding forecasts, analysts offer estimates for Revvity's future value. Examining the current and prior targets provides insight into analysts' changing expectations.

Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Revvity's market position. Stay informed and make well-informed decisions with our Ratings Table.

Stay up to date on Revvity analyst ratings.

Delving into Revvity's Background

Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.

Financial Insights: Revvity

Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.

Decline in Revenue: Over the 3 months period, Revvity faced challenges, resulting in a decline of approximately -6.11% in revenue growth as of 31 December, 2023. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Revvity's net margin is impressive, surpassing industry averages. With a net margin of 11.29%, the company demonstrates strong profitability and effective cost management.

Return on Equity (ROE): Revvity's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 1.01%, the company may encounter challenges in delivering satisfactory returns for shareholders.

Return on Assets (ROA): Revvity's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.58%, the company may encounter challenges in delivering satisfactory returns from its assets.

Debt Management: With a below-average debt-to-equity ratio of 0.52, Revvity adopts a prudent financial strategy, indicating a balanced approach to debt management.

The Significance of Analyst Ratings Explained

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst RatingsBZI-AAR
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!